Frederick W Driscoll
CIK 1129890 · Chief Financial Officer · last filed 2026-07-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
FLXN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3301 AGRICULTURE DRIVE
MADISON, WI 53716
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CLRB | Director | 65 | $1.24 | $81 | $20.2K | 7 | 2026-07-08 |
| LITS | Director | — | $1.16 | — | $0 | 1 | 2025-11-18 |
| Lite Strategy, Inc. (MEIP) Delisted | Director | 1,875 | $3.20 | $6.0K | -$625 | 10 | 2025-07-17 |
| CUE | Director | — | $18.29 | — | $0 | 8 | 2025-01-03 |
| Renovacor, Inc. (RCOR.WS) Delisted | Chief Financial Officer | — | $0.07 | — | $0 | 1 | 2022-03-28 |
| FLXN | Chief Financial Officer | 0 | $24.21 | $0 | -$689.0K | 14 | 2021-11-19 |
| ImmunityBio, Inc. (NK) Delisted | Director | 124,535 | — | — | -$668.1K | 5 | 2020-08-13 |
| Cellectar Biosciences, Inc. (CLRBZ) Delisted | Director | — | $0.12 | — | $0 | 4 | 2020-06-25 |
| Oncotelic Therapeutics, Inc. (OXGN) Delisted | Director | — | — | — | $0 | 4 | 2016-06-03 |
| NVAX | VP, CFO & Treasurer | 1,000 | $9.45 | $9.4K | $23.6K | 7 | 2013-03-06 |
| GENELABS TECHNOLOGIES INC /CA (GNLB) Delisted | CEO | 0 | — | — | $10.0K | 6 | 2009-01-07 |
Recent Filings · Page 6 of 7
67 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-11-26 | FLXN | Other (J) | +1,443 | $17.2K | EDGAR |
| 2014-07-07 | Oncotelic Therapeutics, Inc. (OXGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-03-04 | FLXN | Grant (A) | — | $0 | EDGAR |
| 2014-01-06 | Oncotelic Therapeutics, Inc. (OXGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-03-06 | NVAX | Grant (A) | — | $0 | EDGAR |
| 2012-03-08 | NVAX | Grant (A) | — | $0 | EDGAR |
| 2011-08-11 | NVAX | Buy (P) | +20,000 | $23.6K | EDGAR |
| 2011-03-14 | NVAX | Grant (A) | — | $0 | EDGAR |
| 2010-04-16 | NVAX | Grant (A) | — | $0 | EDGAR |
| 2010-03-17 | NVAX | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.